false
0001445815
0001445815
2024-08-19
2024-08-19
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT TO SECTION 13 OR 15(d)
OF
THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): August 19, 2024
BIOXYTRAN,
INC.
(Exact
Name of Registrant as Specified in Charter)
Nevada |
|
001-35027 |
|
26-2797630 |
(State or Other Jurisdiction |
|
(Commission |
|
(IRS Employer |
of Incorporation) |
|
File Number) |
|
Identification Number) |
75 Second
Ave, Suite 605, Needham, MA |
|
02494 |
(Address of Principal Executive
Offices) |
|
(Zip Code) |
Registrant’s
telephone number, including area code 617-454-1199
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
|
|
|
|
|
Common Stock, par value
$0.001 |
|
BIXT |
|
OTCQB |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
Growth Company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
3.03 Material Modification to Rights of Security Holders
On
August 19, 2024, the Company issued 28,971,248 shares of Convertible Preferred Stock, with a par value of $0.001 per share, to company
insiders in exchange for 94,057,658 shares of Common Stock, at a 5:1 basis, as per the Certificate of Designation dated April 19, 2024,
$353,840 in accrued salaries, accounts receivable and other short-term debt, and of exercise of the conversion rights for the 14,410,000
(49%) Subsidiary shares as per option agreement dated November 20, 2021. The Preferred shares can at any time be converted back into
shares of Common Stock at a 1:5 basis, and carry a voting-power of an “as if converted” basis multiplied by a factor of two.
Preferred Stock (1) | |
Beneficially
Owned | | |
% of class | | |
% voting
rights | |
David Platt (2) whereof indirect 14,091,527 (3) | |
| 22,703,989 | | |
| 78.6 | % | |
| 61.2 | % |
Ola Soderquist (2) | |
| 3,907,060 | | |
| 13.5 | % | |
| 10.5 | % |
Mike Sheikh (2) | |
| 1,600,000 | | |
| 5.5 | % | |
| 4.3 | % |
Alan Hoberman (2) | |
| 226,678 | | |
| 0.8 | % | |
| 0.6 | % |
Anders Utter (2) | |
| 215,838 | | |
| 0.7 | % | |
| 0.6 | % |
Dale Conaway (2) | |
| 212,018 | | |
| 0.7 | % | |
| 0.6 | % |
Radka Milanova (2) | |
| 36,529 | | |
| 0.1 | % | |
| 0.1 | % |
All officers and Directors as a Group (7 persons) | |
| 28,971,248 | | |
| 100.0 | % | |
| 77.9 | % |
(1) |
There
are 49,500,000 authorized shares of Convertible Preferred Stock, and 28,971,248 outstanding |
(2) |
The
business address of these individuals is 75 2nd Ave., Suite 605, Needham, MA 02494. |
(3) |
On
behalf of Naomi Platt (spouse of David Platt) and of NDPD Pharma, Inc., where the beneficial ownership includes the Company’s
officers. |
As
a consequence of these transactions, the Company’s amount of registered shares of Common Stock, pursuant to Section 12(b) of the
Act, and listed on the OTCMarkets QB exchange was reduced to 81,850,495 shares, whereof 34,714,377 (42%) are held at DTC.
Item
8.01 Other Events
On
Wednesday, August 21, 2024, the Company will issue a press-release in reference to a recent article “The Involvement of Carbon
Monoxide in Mitochondrial Activity and Brain Functions”. The article is written by Avraham Mayevsky, CTO of the Company’s
affiliate MDX Lifesciences and was published in the British
Journal of Healthcare and Medical Research.
The
press-release will be published over EIN Presswire under the title:
Bioxytran
Measures the Presence of Carbon Monoxide When BXT-25 Delivers Oxygen to the Brain
Item
9.01 Financial Statements and Exhibits.
* |
Filed as an exhibit
hereto. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
BIOXYTRAN, INC. |
|
|
|
|
By: |
/s/ David
Platt, Ph.D. |
|
|
David Platt, Ph.D., its Chief Executive Officer |
|
|
|
Date August 19, 2024 |
|
|
Exhibit 99.1
Bioxytran Measures the Presence of Carbon Monoxide
When BXT-25 Delivers Oxygen to the Brain
British Journal Article Elucidates the Effects of
Carbon Monoxide in Mitochondrial Activity
BOSTON, MASSACHUSETTS, August 24, 2024 (EIN
Presswire) — BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing
oral and intravenous drugs to treat COVID-19, other viral diseases, fibrosis, and the development of BXT-25 for stroke, dementia, Alzheimer’s
Disease. MDX Life Sciences, an affiliate of Bioxytran, the developer of the MDX Viewer for use to validate delivery of oxygen by BXT-25.
In an article authored by Prof. Avraham Mayevsky,
CTO of MDX Life Sciences, announced that the British Journal of Healthcare and Medical Research published a peer-reviewed article titled
“The Involvement of Carbon Monoxide in Mitochondrial Activity and Brain Functions”. The article describes how Carbon Monoxide
poisoning effects the metabolic function of the brain. The tests conducted in the study used Bioxytran’s FDA approved MDX viewer
which provides a real-time readout of tissue metabolic score in the animals.
https://doi.org/10.14738/bjhmr.112.16760
“The MDX Viewer is an essential tool in quantifying
the impact of oxygen on the brain and various organs,” said Professor Mayevsky. “The animal studies show us that that each
is unique and consumes oxygen at different rates and that the MDX Viewer has the ability to measure the individual impact on the animal
with real time monitoring. What we have here is a very powerful model to quantify the impact of oxygen on the brain and other vital organs.
The model virtually eliminates the variability from animal to animal enabling us to really measure the impact that various inputs like
Carbon Monoxide to start with.”
These studies support the rationale behind the development
of BXT-25 for stroke, dementia, Alzheimer’s’ Disease, and Parkinson’s disease. The article independently supports Bioxytran’s
drug development program for hypoxia and degenerative diseases.
About Bioxytran, Inc.
Bioxytran, Inc. is a clinical stage biotechnology
company pioneering a library of novel carbohydrate structures using artificial intelligence software that interprets the Nuclear Magnetic
Resonance imaging of druggable targets like the galectin fold to create a rational drug design. The leading drug candidates vetted by
in vitro testing, are capable of neutralizing viruses. The peer-reviewed discovery of the galectin fold located on the spike proteins
of viruses such as COVID-19, RSV, and H1N1 demonstrate there exists a conserved region on the spike in which Bioxytran’s molecules
achieve virus neutralization. The extent of the carbohydrate structure’s ability to neutralize untested viruses is unknown just
like the initial discovery of antibiotics last century and its ability to treat a broad spectrum of bacterial infections. Applications
of this platform technology extend to the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia.
The leading drug candidate, Prolectin-M, is a new class of antiviral drug designed to antagonize galectins implicated in inflammatory,
fibrotic, and malignant diseases. Bioxytran’s other development programs are for pulmonary fibrosis and stroke treatment. More information
can be found at www.bioxytraninc.com
Investor Relations
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com
Forward-Looking Statements
This press release includes forward-looking statements
as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking
statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,”
“intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying
words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s
actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking
statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and those risk
factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to
correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent
required under federal securities laws.
v3.24.2.u1
Cover
|
Aug. 19, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Aug. 19, 2024
|
Entity File Number |
001-35027
|
Entity Registrant Name |
BIOXYTRAN,
INC.
|
Entity Central Index Key |
0001445815
|
Entity Tax Identification Number |
26-2797630
|
Entity Incorporation, State or Country Code |
NV
|
Entity Address, Address Line One |
75 Second
Ave
|
Entity Address, Address Line Two |
Suite 605
|
Entity Address, City or Town |
Needham
|
Entity Address, State or Province |
MA
|
Entity Address, Postal Zip Code |
02494
|
City Area Code |
617
|
Local Phone Number |
454-1199
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, par value
$0.001
|
Trading Symbol |
BIXT
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14a -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Bioxytran (QB) (USOTC:BIXT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Bioxytran (QB) (USOTC:BIXT)
Historical Stock Chart
From Oct 2023 to Oct 2024